Skin Cancer

SKIN CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Tumor-Infiltrating Lymphocytes Outperform Ipilimumab in Advanced Melanoma

Tumor-infiltrating lymphocytes can improve progression-free survival, when compared with ipilimumab, in patients with advanced melanoma, a phase 3 trial suggests.
First-Line Immune Checkpoint Inhibitors Underused in Metastatic Melanoma

First-line immune checkpoint inhibitors have improved survival in patients with metastatic melanoma but remain underused in this population.
Low-Dose Methotrexate May Increase Risk of Melanoma

Exposure to low-dose methotrexate is associated with an increased risk of melanoma, according to a meta-analysis of 17 studies.
No Survival Benefit With T-VEC in Advanced Melanoma

Adding T-VEC to pembrolizumab does not improve survival in patients with advanced melanoma, a phase 3 study suggests.
Disparities in Use of Immunotherapies Persist After FDA Approval

Some disparities that existed before FDA approval persisted after approval, and some new disparities emerged after FDA approval.

SKIN CANCER NEWS

Doctor showing tablet to patient.

Melanoma Diagnosis Linked to Increased Risk of Prostate Cancer

November 30, 2022

IV infusion

QOL Up With Pembrolizumab vs Ipilimumab, HDI in Resected Melanoma

November 29, 2022

Accredited Hospitals Fail to Disclose Costs of Common Cancer Surgeries

November 28, 2022

Doctor examining patient's skin.

Lack of Consensus Regarding Follow-Up After Keratinocyte Carcinoma Treatment

November 18, 2022

Melanoma

Subset of Stage I Melanoma Patients Have Very Low Mortality Rate

November 8, 2022

Next post in Skin Cancer

QOL Up With Pembrolizumab vs Ipilimumab, HDI in Resected Melanoma